Drugs / HY07121
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06639256 | Oct 2024 → May 2026 overdue | — | Sichuan Huiyu Pharmaceutical Co., Ltd | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HY07121 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06639256 ↗ |
| Route | Intravenous | “administered intravenously” NCT06639256 ↗ |